HIGHLIGHTS
- who: Kathryn A. Skelding and collaborators from the Medicine and Wellbeing, The University of Newcastle, Callaghan, NSW, Australia have published the paper: Bone Marrow Microenvironment as a Source of New Drug Targets for the Treatment of Acute Myeloid Leukaemia, in the Journal: (JOURNAL)
- what: The main focus of this review is on drugs that modulate/target this marrow microenvironment and have been examined in in vivo models or clinically. This study demonstrated that the addition of bevacizumab to standard chemotherapy did not improve the therapeutic outcome for older AML patients and suggests that bevacizumab may . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.